Abstract
Multiple sclerosis is an autoimmune demyelinating disorder of the central nervous system that shares similar immunopathogenic mechanisms with chronic plaque psoriasis, such as the overexpression of the Th17 pathway. We report the case of a patient with multiple sclerosis and severe chronic plaque psoriasis successfully treated with ixekizumab (anti IL-17A and IL-17A/F monoclonal antibody). The treatment achieved a complete skin clearance (PASI 100 response) with no adverse events or evidence of progression of the neurological disease.
Publication Date
8-29-2021
First Page
488
Last Page
490
Creative Commons License
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 International License.
Recommended Citation
Herrera-Acosta, Enrique; Martina, Gustavo Guillermo Garriga; Suárez-Pérez, Jorge Alonso; Martínez-García, Eliseo Alejandro; and Herrera-Ceballos, Enrique
(2021)
"Ixekizumab for patients with plaque psoriasis affected by multiple sclerosis,"
Sultan Qaboos University Medical Journal: Vol. 21: 488-490.
DOI: https://doi.org/10.18295/squmj.4.2021.021
